FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024479430> ?p ?o ?g. }

• W2024479430 abstract "<h3>Objective</h3> To determine if neutralizing antibodies (NAbs) against interferon beta from patients with multiple sclerosis (MS) cross-react with other type 1 interferons, especially endogenous interferon beta, and thus might impede the immune systems of affected patients. <h3>Design</h3> Masked serum samples from MS patients were challenged in vitro against recombinant interferon beta-1a and interferon beta-1b, as well as human leukocyte interferon and fibroblast interferon, the latter representing endogenous interferon. The neutralizing capacity of serum samples on these type 1 interferons was assessed using a luciferase reporter gene assay. Randomly selected samples were titrated to further delineate the cross-reactivity of antibodies. <h3>Setting</h3> University medical center in Düsseldorf, Germany. <h3>Patients</h3> We randomly selected 150 samples from interferon beta–treated MS patients who had previously been tested for the presence of binding antibodies and NAbs. <h3>Main Outcome Measures</h3> Neutralization of interferon beta bioactivity and cross-reactivity of anti–interferon beta antibodies. <h3>Results</h3> Antibody-mediated neutralization of interferon beta bioactivity in vitro against recombinant interferon beta was observed in all serum samples that had previously tested positive for binding antibodies and NAbs. A neutralizing pattern comparable to that of recombinant interferon beta was observed when endogenous interferon was assessed, reflecting cross-reactivity of NAbs. No differences in neutralization between recombinant and endogenous interferon were observed with respect to the interferon beta preparation used for treatment. Furthermore, no neutralization of other type 1interferons by NAbs could be detected. <h3>Conclusions</h3> A proportion of MS patients who are treated with recombinant interferon beta develop NAbs that also neutralize endogenous interferon. Because NAbs at high titers can persist for years, these antibodies may impede the immune system in affected MS patients regardless of their current treatment regimen." @default.
• W2024479430 created "2016-06-24" @default.
• W2024479430 creator A5023893355 @default.
• W2024479430 creator A5031075667 @default.
• W2024479430 creator A5033563429 @default.
• W2024479430 creator A5041150149 @default.
• W2024479430 creator A5053300118 @default.
• W2024479430 creator A5057689639 @default.
• W2024479430 creator A5063615479 @default.
• W2024479430 creator A5082233226 @default.
• W2024479430 date "2010-09-01" @default.
• W2024479430 modified "2023-09-27" @default.
• W2024479430 title "Inhibition of Endogenous Interferon Beta by Neutralizing Antibodies Against Recombinant Interferon Beta" @default.
• W2024479430 cites W1910043311 @default.
• W2024479430 cites W1975995030 @default.
• W2024479430 cites W1979325667 @default.
• W2024479430 cites W2000659642 @default.
• W2024479430 cites W2017486126 @default.
• W2024479430 cites W2025240311 @default.
• W2024479430 cites W2029745420 @default.
• W2024479430 cites W2049440942 @default.
• W2024479430 cites W2060230637 @default.
• W2024479430 cites W2061374640 @default.
• W2024479430 cites W2069361946 @default.
• W2024479430 cites W2076118869 @default.
• W2024479430 cites W2078844752 @default.
• W2024479430 cites W2095007655 @default.
• W2024479430 cites W2096729247 @default.
• W2024479430 cites W2100586502 @default.
• W2024479430 cites W2129012981 @default.
• W2024479430 cites W2152726857 @default.
• W2024479430 cites W2164490190 @default.
• W2024479430 cites W2167043889 @default.
• W2024479430 cites W2169604625 @default.
• W2024479430 cites W2485483395 @default.
• W2024479430 doi "https://doi.org/10.1001/archneurol.2010.218" @default.
• W2024479430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20837854" @default.
• W2024479430 hasPublicationYear "2010" @default.
• W2024479430 type Work @default.
• W2024479430 sameAs 2024479430 @default.
• W2024479430 citedByCount "22" @default.
• W2024479430 countsByYear W20244794302012 @default.
• W2024479430 countsByYear W20244794302013 @default.
• W2024479430 countsByYear W20244794302014 @default.
• W2024479430 countsByYear W20244794302015 @default.
• W2024479430 countsByYear W20244794302017 @default.
• W2024479430 countsByYear W20244794302018 @default.
• W2024479430 countsByYear W20244794302019 @default.
• W2024479430 countsByYear W20244794302020 @default.
• W2024479430 countsByYear W20244794302021 @default.
• W2024479430 countsByYear W20244794302022 @default.
• W2024479430 crossrefType "journal-article" @default.
• W2024479430 hasAuthorship W2024479430A5023893355 @default.
• W2024479430 hasAuthorship W2024479430A5031075667 @default.
• W2024479430 hasAuthorship W2024479430A5033563429 @default.
• W2024479430 hasAuthorship W2024479430A5041150149 @default.
• W2024479430 hasAuthorship W2024479430A5053300118 @default.
• W2024479430 hasAuthorship W2024479430A5057689639 @default.
• W2024479430 hasAuthorship W2024479430A5063615479 @default.
• W2024479430 hasAuthorship W2024479430A5082233226 @default.
• W2024479430 hasConcept C104317684 @default.
• W2024479430 hasConcept C14086860 @default.
• W2024479430 hasConcept C159047783 @default.
• W2024479430 hasConcept C159654299 @default.
• W2024479430 hasConcept C199360897 @default.
• W2024479430 hasConcept C202751555 @default.
• W2024479430 hasConcept C203014093 @default.
• W2024479430 hasConcept C2776174256 @default.
• W2024479430 hasConcept C2776178377 @default.
• W2024479430 hasConcept C2779261636 @default.
• W2024479430 hasConcept C2909179924 @default.
• W2024479430 hasConcept C2910198813 @default.
• W2024479430 hasConcept C2994247566 @default.
• W2024479430 hasConcept C40767141 @default.
• W2024479430 hasConcept C41008148 @default.
• W2024479430 hasConcept C55493867 @default.
• W2024479430 hasConcept C86803240 @default.
• W2024479430 hasConceptScore W2024479430C104317684 @default.
• W2024479430 hasConceptScore W2024479430C14086860 @default.
• W2024479430 hasConceptScore W2024479430C159047783 @default.
• W2024479430 hasConceptScore W2024479430C159654299 @default.
• W2024479430 hasConceptScore W2024479430C199360897 @default.
• W2024479430 hasConceptScore W2024479430C202751555 @default.
• W2024479430 hasConceptScore W2024479430C203014093 @default.
• W2024479430 hasConceptScore W2024479430C2776174256 @default.
• W2024479430 hasConceptScore W2024479430C2776178377 @default.
• W2024479430 hasConceptScore W2024479430C2779261636 @default.
• W2024479430 hasConceptScore W2024479430C2909179924 @default.
• W2024479430 hasConceptScore W2024479430C2910198813 @default.
• W2024479430 hasConceptScore W2024479430C2994247566 @default.
• W2024479430 hasConceptScore W2024479430C40767141 @default.
• W2024479430 hasConceptScore W2024479430C41008148 @default.
• W2024479430 hasConceptScore W2024479430C55493867 @default.
• W2024479430 hasConceptScore W2024479430C86803240 @default.
• W2024479430 hasIssue "9" @default.
• W2024479430 hasLocation W20244794301 @default.
• W2024479430 hasLocation W20244794302 @default.
• W2024479430 hasOpenAccess W2024479430 @default.
• W2024479430 hasPrimaryLocation W20244794301 @default.
• W2024479430 hasRelatedWork W1972745941 @default.

• next